In Silico Methods
Computational approaches to drug development—using AI, machine learning, and molecular modeling to predict human responses without animal testing
from nam_models import ToxicityPredictor
# Load human-specific model trained on clinical data
model = ToxicityPredictor(species="human")
# Predict hepatotoxicity risk
risk = model.predict_liver_toxicity(compound)
print(f"Human hepatotoxicity risk: {risk}")
# No animals required. Human-relevant predictions.
Computational Approaches
From molecular modeling to AI-driven predictions
QSAR Models
Quantitative Structure-Activity Relationship models that predict biological activity from molecular structure.
- ✓ Predicts toxicity endpoints
- ✓ FDA-accepted for submissions
- ✓ Rapid screening of thousands
- ✓ Trained on human data
Molecular Dynamics
Simulations of how molecules move and interact at the atomic level, predicting drug-target binding.
- ✓ Binding affinity prediction
- ✓ Protein-drug interactions
- ✓ Conformational analysis
- ✓ Mechanism insights
Virtual Screening
Computational screening of millions of compounds against a target to identify promising drug candidates.
- ✓ Screens millions of compounds
- ✓ Docking simulations
- ✓ Pharmacophore matching
- ✓ Prioritizes lab testing
PBPK Modeling
Physiologically-Based Pharmacokinetic models that simulate drug absorption, distribution, metabolism, and excretion.
- ✓ Human body simulation
- ✓ Dose prediction
- ✓ Drug-drug interactions
- ✓ Population variability
Deep Learning Toxicity
Neural networks trained on millions of human toxicity data points to predict adverse effects from molecular structure.
Generative Drug Design
AI systems that design novel molecules optimized for efficacy, safety, and human-specific metabolism.
Clinical Trial Prediction
ML models that predict clinical trial outcomes based on preclinical data, identifying likely failures early.
Target Identification
AI analysis of human genomics and proteomics data to identify new drug targets for diseases.
In Silico Drug Development Pipeline
How computational methods accelerate discovery
Target Analysis
AI identifies human disease targets from genomic data
Virtual Screening
Screen millions of compounds computationally
ADMET Prediction
Predict human absorption, metabolism, toxicity
Lead Optimization
AI suggests molecular improvements
In Vitro Validation
Test top candidates in human cell models
What In Silico Can Predict
Human-relevant endpoints without animal testing
Hepatotoxicity
Predict liver toxicity using models trained on human hepatocyte data and clinical adverse event reports.
Cardiotoxicity
hERG channel binding prediction and QT prolongation risk using human ion channel models.
Mutagenicity
Ames test prediction and DNA binding assessment using validated QSAR models.
Skin Sensitization
Predict allergic reactions using models trained on human clinical data, replacing guinea pig tests.
Drug Metabolism
CYP450 enzyme interactions and metabolite prediction specific to human liver enzymes.
Blood-Brain Barrier
Predict CNS penetration based on human BBB permeability data and transporter interactions.
Regulatory Acceptance
FDA, EMA, and other agencies accept in silico data for regulatory submissions. OECD has validated multiple QSAR models for toxicity endpoints, and the FDA's CDER encourages computational approaches in drug development.